Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing and Issue of Equity

9 Nov 2017 18:19

RNS Number : 1101W
Diurnal Group PLC
09 November 2017
 

9 November 2017

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealing and Issue of Equity

 

On 8 November 2017, Diurnal issued a total of 109,296 new ordinary shares of 5 pence in the Company ("Shares") under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), including 69,565 new Shares to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total number of Shares issued

Nature of issuance

Martin Whitaker

69,565

Vesting of Deferred Bonus Award

 

The Shares issued were awarded on a deferred basis on 8 November 2016, as previously notified on 9 November 2016. Upon receipt of these shares, Martin Whitaker subsequently sold 33,650 ordinary shares to settle payment of all tax and NI requirements in relation to the award as set out in the notification below.

 

Issue of equity

 

Application has been made to AIM for the admission of the 109,296 new Shares, which is anticipated to occur at 8.00am on 15 November 2017. The Company has also made application for admission to AIM at the same time of the following shares that have previously been duly issued and allotted but not admitted to trading: 110,000 new Shares issued on 12 April 2017 in respect of the exercise of options by a former employee at an exercise price of 43.77p per new Share; 10,791 new Shares issued on 7 September 2017 in respect of the vesting of shares to Mr John Goddard, NED of the Company, at a price of 5p per new Share (as announced on 7 September 2017); 100,000 new Shares issued on 21 September 2017 in respect of the exercise of options by a former director at an exercise price of 0.2p per new Share; and 29,000 new Shares issued on 21 September 2017 in respect of the exercise of options by an employee at an exercise price of 43.77p per new Share.

 

Following admission of the new Shares, the Company's total issued share capital will be 52,569,846 Ordinary Shares. Therefore, the total number of voting rights in the Company is 52,569,846. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

 

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Vesting of awards under the Diurnal Group plc Long Term Incentive Plan as follows:

 

EMI deferred bonus award over 9,730 ordinary shares.

 

Non-EMI deferred bonus award over 59,835 ordinary shares.

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

120p

9,730

120p

59,835

d)

 

Aggregated information

- Aggregated volume

69,565 ordinary shares

- Price

£83,478.00

e)

 

Date of the transaction

 

8 November 2017

f)

 

Place of the transaction

 

Off market

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

 

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Sale of 33,650 shares

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

134.7p per share

33,650

d)

 

Aggregated information

- Aggregated volume

33,650 ordinary shares

- Price

£45,326.55

e)

 

Date of the transaction

 

8 November 2017

f)

 

Place of the transaction

 

XLON

 

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield

Corporate Broking: James Black

Panmure Gordon (UK) Limited (Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley / Duncan Monteith

Corporate Broking: Tom Salvesen

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFSIFAUFWSEFF
Date   Source Headline
9th Jan 20187:00 amRNSPositive results from Alkindi food matrix study
9th Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
5th Jan 20185:06 pmRNSIssue of Equity
5th Jan 20185:04 pmRNSReplacement - Director Dealings
5th Jan 20181:19 pmRNSDirector Dealings
19th Dec 201712:53 pmRNSHardman Research: Alkindi®: On route to Europe
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
15th Dec 201712:11 pmRNSCHMP positive opinion for Alkindi® (Infacort®)
8th Dec 201711:30 amRNSTotal Voting Rights
29th Nov 201712:20 pmRNSDirector/PDMR Shareholding
21st Nov 201712:00 pmRNSResult of AGM
9th Nov 20176:19 pmRNSDirector Dealing and Issue of Equity
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
13th Oct 20179:00 amRNSPosting of Annual Report and AGM Notice
15th Sep 20177:00 amRNSInfacort® data published in Clinical Endocrinology
14th Sep 20177:15 amRNSHardman Research: Ready to press the button
7th Sep 20172:51 pmRNSDirector Dealings
6th Sep 20177:00 amRNSGrant of first US patent for Chronocort®
6th Sep 20177:00 amRNSResults for the year ended 30 June 2017
14th Aug 201710:00 amRNSNotice of Final Results
15th Jun 20177:00 amRNSFirst Patient Dosed in US Infacort Clinical Trial
18th May 20177:00 amRNSGrant of first US patent for Infacort
8th May 201710:03 amRNSDirector/PDMR Shareholding
27th Mar 20177:15 amRNSHardman Research:Commercial and development update
20th Mar 20177:00 amRNSInterim Results for the 6 Months Ended 31 Dec 2016
16th Mar 20177:00 amRNSLaunch of a European Patient Access programme
2nd Mar 20177:00 amRNSMarketing and Distribution Agreement
1st Mar 20177:00 amRNSNotice of Interim Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUpdate on Commercial Pre-Launch Activities
19th Jan 20177:15 amRNSHardman Research: Infacort® - On track to market
17th Jan 20173:30 pmRNSDirector Dealings
16th Jan 20177:00 amRNSDirectors' Dealings
12th Jan 20177:00 amRNSAppointment of Chief Financial Officer
4th Jan 20173:38 pmRNSHolding(s) in Company
20th Dec 201612:08 pmRNSSubmission of Infacort® European PUMA Application
23rd Nov 201611:30 amRNSResults of Annual General Meeting
21st Nov 20167:00 amRNSFirst Patient Dosed in Testosterone Trial
9th Nov 20169:36 amRNSDirector/PDMR Shareholding
27th Oct 20167:15 amRNSHardman Research: Get the Rhythm
12th Oct 20167:00 amRNSFull Infacort Phase III Data Analysis
12th Oct 20167:00 amRNSFinal Results June 2016
12th Sep 20167:00 amRNSNotice of Results
11th Jul 20167:00 amRNSPositive headline data Infacort pivotal study
12th Apr 201612:15 pmRNSGrants of options and award of conditional shares
30th Mar 20167:00 amRNSHalf Yearly Report
22nd Mar 20163:00 pmRNSNotice of Results
29th Feb 20167:00 amRNSFirst patient dosed in Chronocort® pivotal study
19th Jan 20163:32 pmRNSHolding(s) in Company
5th Jan 20163:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.